Dr. Reddy's Launches Generic Bosutinib 400mg in US, First-to-Market
Dr. Reddy's launched Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the US on June 13, 2026. This marks a first-to-market entry and secures 180 days of exclusivity. The Bosulif® brand had US sales of approximately $253.8 million for the 12 months ended April 2026.
The launch of a generic drug in the US market, particularly in the oncology segment, can have a significant impact on revenue and market share. The previous sales of the branded drug indicate a substantial market opportunity.
The launch of a generic drug, especially a first-to-market entry with exclusivity, is positive for the company as it expands its portfolio and market presence in a key therapeutic area.
Dr. Reddy's Laboratories announced on June 13, 2026, the first-to-market launch of Bosutinib Tablets 400mg in the United States. This generic equivalent of Bosulif® is an oncology drug belonging to the Tyrosine Kinase Inhibitor category. The launch expands Dr. Reddy's oncology portfolio and aims to improve patient access to affordable, high-quality medicines.
The product is a first-to-file product and is eligible for 180 days of generic drug exclusivity for this strength in the U.S. Dr. Reddy's has collaborated with MSN Laboratories Private Limited for this product, with MSN responsible for its development and manufacturing. Dr. Reddy's holds the exclusive marketing rights in the United States.
Milan Kalawadia, CEO - North America at Dr. Reddy's Laboratories, Inc., stated that the launch underscores the company's commitment to timely market entry for high-priority therapies and broadening access for patients and healthcare providers. Bharat Reddy, Executive Director at MSN Laboratories, highlighted MSN's capabilities in developing and commercializing complex oncology products.
The Bosulif® brand (400mg) had U.S. sales of approximately $253.8 million for the 12-month period ended April 2026, according to IQVIA data.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.